

Pharmasset Inc  
Form S-8 POS  
January 18, 2012

As filed with the Securities and Exchange Commission on January 18, 2012

Registration No. 333-174055

Registration No. 333-162359

Registration No. 333-142630

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**POST-EFFECTIVE AMENDMENT NO. 1**  
**TO**  
**FORM S-8**  
**REGISTRATION STATEMENT NO. 333-174055**  
**POST-EFFECTIVE AMENDMENT NO. 1**  
**TO**  
**FORM S-8**  
**REGISTRATION STATEMENT NO. 333-162359**  
**POST-EFFECTIVE AMENDMENT NO. 1**

**TO**  
**FORM S-8**  
**REGISTRATION STATEMENT NO. 333-142630**  
*UNDER*  
*THE SECURITIES ACT OF 1933*

**PHARMASSET INC.**

(Exact Name of Registrant as Specified in its Charter)

**Delaware**  
(State or Other Jurisdiction of  
Incorporation or Organization)

**98-0406340**  
(I.R.S. Employer  
Identification Number)

**303-A College Road East**

**Princeton, New Jersey 08540**

**(609) 613-4100**

(Address, including zip code, and telephone number, including area code, of Registrant's principal executive offices)

**Pharmasset, Inc. 1998 Stock Plan, as amended**

**Pharmasset, Inc. 2007 Equity Incentive Plan, as amended**

(Full titles of the Plans)

**Brett A. Pletcher, Esq.**

Edgar Filing: Pharmasset Inc - Form S-8 POS

**Senior Vice President and General Counsel**

**Gilead Sciences, Inc.**

**333 Lakeside Drive**

**Foster City, California 94404**

**(650) 574-3000**

(Name, address, including zip code, and telephone number, including area code, of agent for service)

*Copy to:*

**Franklin M. Gittes, Esq.**

**Stephen F. Arcano, Esq.**

**Brandon Van Dyke, Esq.**

**Skadden, Arps, Slate, Meagher & Flom LLP**

**4 Times Square**

**New York, New York 10036**

**(212) 735-3000**

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer ☐

Accelerated filer ☐

Non-accelerated filer ☐ (Do not check if a smaller reporting company)

Smaller reporting company ☐

**RECENT EVENTS: DEREGISTRATION OF SECURITIES**

This Post-Effective Amendment relates to the following Registration Statements of Pharmasset, Inc. ( Pharmasset ) on Form S-8, in each case as amended by any post-effective amendments thereto (collectively, the Registration Statements ):

Registration Statement No. 333-174055, registering 2,000,000 shares of Pharmasset s common stock, par value \$0.001 ( Company Common Stock ), under the Pharmasset 1998 Stock Plan, as amended;

Registration Statement No. 333-162359, registering 1,000,000 shares of Company Common Stock under the Pharmasset 2007 Equity Incentive Plan, as amended; and

Registration Statement No. 333-142630, registering 2,719,166 shares of Company Common Stock under the Pharmasset 1998 Stock Plan, as amended and registering 1,169,705 shares of Company Common Stock under the Pharmasset 2007 Equity Incentive Plan, as amended.

Pharmasset, Gilead Sciences, Inc., a Delaware corporation ( Gilead ), and Royal Merger Sub Inc., a Delaware corporation and direct wholly-owned subsidiary of Gilead ( Merger Sub ), entered into an Agreement and Plan of Merger dated as of November 21, 2011 (the Merger Agreement ) (the rights of which thereunder were assigned to Royal Merger Sub II Inc., a Delaware corporation and indirect wholly-owned subsidiary of Gilead, on January 12, 2012) ( Merger Sub II ), pursuant to which, among other things, Merger Sub II would merge with and into Pharmasset (the Merger ), Pharmasset would become a wholly-owned subsidiary of Gilead, and all outstanding shares of Company Common Stock would be converted into the right to receive \$137 in cash. The Merger became effective on January 17, 2012 (the Effective Time ) following the filing of a Certificate of Ownership and Merger with the Secretary of State of the State of Delaware.

As a result of the Merger, Pharmasset has terminated any and all offerings of its securities pursuant to the Registration Statements. Accordingly, Pharmasset hereby terminates the effectiveness of each Registration Statement and, in accordance with an undertaking made by Pharmasset in Part II of each Registration Statement to remove from registration, by means of a post-effective amendment, any securities that had been registered for issuance but remain unsold at the termination of the offering, removes from registration any and all securities of Pharmasset registered but unsold under the Registration Statements as of the Effective Time.

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment No. 1 to Registration Statements on Form S-8 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Foster City, State of California, on January 18, 2012.

**PHARMASSET, INC.**

By: /s/ John F. Milligan, Ph.D.  
Name: John F. Milligan, Ph.D.  
Title: President

Pursuant to the requirements of the Securities Act of 1933, as amended, this Post-Effective Amendment to the Registration Statements has been signed by the following persons in the capacities and on the dates indicated.

<b>Signature</b>	<b>Title</b>	<b>Date</b>
/s/ John F. Milligan, Ph.D. John F. Milligan, Ph.D.	President and Director	January 18, 2012
/s/ Robin L. Washington Robin L. Washington	Chief Financial Officer and Director	January 18, 2012
/s/ Brett A. Pletcher Brett A. Pletcher	Secretary and Director	January 18, 2012